Tranilast: A Pharmaceutical Candidate for Reduction of Adhesions Using a Novel Approach

Janel Petrilli; Scott Wadsworth; Kevin Cooper; Kathleen E. Rodgers; John Siekierka; Gere S. diZerega

doi:10.1055/s-0028-1082392

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2008; 26(4): 341-348
DOI: 10.1055/s-0028-1082392

Tranilast: A Pharmaceutical Candidate for Reduction of Adhesions Using a Novel Approach

Janel Petrilli¹ , Scott Wadsworth¹ , Kevin Cooper² , Kathleen E. Rodgers³ , John Siekierka¹ , Gere S. diZerega³

¹Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey
²Center for Biomaterials & Advanced Technologies, Medical Devices Group, A division of Ethicon, A Johnson & Johnson Company, Somerville, New Jersey
³University of Southern California, Keck School of Medicine, Department of Obstetrics & Gynecology, Livingston Reproductive Biology Laboratories, Los Angeles, California

Abstract

ABSTRACT

Postsurgical adhesion formation has numerous deleterious side effects in a wide variety of surgical settings. Physical barriers used together with laparoscopy were developed in hopes of reducing the tissue trauma seen with open procedures and separating tissues during the critical time of healing to reduce adhesion formation. Despite meticulous techniques by surgeons and the availability of barriers, adhesion formation remains a serious problem, with more than $1 billion spent annually on complications arising from adhesions. Our laboratories have combined a previously marketed drug, Tranilast, with a gel to provide a locally delivered medicated device that can reduce adhesion formation. This article will review the role of Tranilast in the key pathways involved in adhesion formation.

KEYWORDS

Transilast - adhesions - mast cells - gynecologic surgery - surgery

Full Text

References

REFERENCES

1 Ray T, Larson Jr J W, Stillman R J, Jacobs R J. Economic impact of hospitalizations for lower abdominal adhesiolysis in the United States in 1988. Surg Gynecol Obstet. 1993; 176 271-276
2 Diamond M P, DeCherney A H. Pathogenesis of adhesion formation/reformation: application to reproductive pelvic surgery. Microsurgery. 1987; 8 103-107
3 Diamond M P, Daniell J F, Feste J et al.. Adhesion reformation and de novo adhesion formation following reproductive pelvic surgery. Fertil Steril. 1987; 47 864-866
4 Operative Laparoscopy Study Group . Postoperative adhesion development following operative laparoscopy: evaluation at early second-look procedures. Fertil Steril. 1991; 55 700
5 Diamond M P. Surgical aspects of infertility. In: Speroff L, Simpson JL, Sciarra JJ Obstetrics and Gynecology. Vol 5. Philadelphia, PA; JB Lippincott 1991: 1-23
6 Ray N F, Denton W G, Thamer M, Henderson S C, Perry S. Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994. J Am Coll Surg. 1998; 186 1-9
7 Ellis H, Moran B J, Thompson J N et al.. Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study. Lancet. 1999; 353 1476-1480
8 Kamffer W J, Jooste E V, Nel J T, de Wet J I. Surgical glove powder and intraperitoneal adhesion formation. An appeal for the use of powder-free surgical gloves. S Afr Med J. 1992; 81 158-159
9 Weibel M A, Majno G. Peritoneal adhesions and their relation to abdominal surgery. A postmortem study. Am J Surg. 1973; 126 345-353
10 Myllarniemi H, Frilander M, Turunen M, Saxen L. The effect of glove powders and their constituents on adhesion and granuloma formation in the abdominal cavity of rabbit. Acta Chir Scand. 1966; 131 312-318
11 Interceed (TC7) Adhesion Barrier Study Group . Prevention of postsurgical adhesions by Interceed (TC7), an absorbable adhesion barrier: a prospective, randomized multicenter clinical study. Fertil Steril. 1989; 51 933-938
12 Surrey M W, Friedman S. Second-look laparoscopy after reconstructive pelvic surgery for infertility. J Reprod Med. 1982; 27 658-660
13 diZerega G S. Contemporary adhesion prevention. Fertil Steril. 1994; 61 219-235
14 Galli S J, Gordon J R, Wershil B K. Mast cell cytokines in allergy and inflammation. Agents Actions Suppl. 1993; 43 209-220
15 Collins S M. The immunomodulation of gut motility: factors that determine the proliferation of mast cells in the sensitized gut. Gastroenterology. 1988; 94 74
16 Liebman S M, Langer J C, Marshall J S, Collins S M. Role of mast cells in peritoneal adhesion formation. Am J Surg. 1993; 165 127-130
17 Langer J C, Liebman S M, Monk P K, Pelletier G J. Mast cell mediators and peritoneal adhesion formation in the rat. J Surg Res. 1995; 59 344-348
18 Xu X, Pappo O, Garbuzenko E, Bischoff S C, Rivkind A, Levi-Schaffer F. Mast cell dynamics and involvement in the development of peritoneal adhesion in the rat. Life Sci. 2002; 70 951-967
19 Levi-Schaffer F, Weg V B. Mast cells, eosinophils and fibrosis. Clin Exp Allergy. 1997; 11 64-70
20 Levi-Schaffer F, Kupietzky A. Mast cells enhance migration and proliferation of fibroblasts into an in vitro wound. Exp Cell Res. 1990; 188 42-49
21 Kupietzky A, Levi-Schaffer F. The role of mast cells-derived histamine in the closure of an in vitro wound. Inflamm Res. 1996; 45 176-180
22 Hatamochi A, Ueki H, Mauch C, Krieg T. Effect of histamine on collagen and non-collagen mRNA production in human skin fibroblasts. J Dermatol. Sci. 1991; 2 407-412
23 Claman H. Mast cells, T cells and abnormal fibrosis. Immunol Today. 1985; 6 192
24 Adachi S, Maruyama T, Kondo T, Todoroki T, Fukao K. Prevention of postoperative intraperitoneal adhesions by tranilast: N-(3′,4′-dimethoxycinnamoyl)anthranilic acid. Surg Today. 1999; 29 51-54
25 Holmdahl L. The role of fibrinolysis in adhesion formation. Eur J Surg Suppl. 1997; 557 24-31
26 Rubin J, Herrera G A, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1991; 18 97-102
27 Remick D G, Strieter M, Lynch III J P, Nguyen D, Eskandari M, Kunkel S L. In vivo dynamics of murine tumor necrosis factor-alpha gene expression. Lab Invest. 1989; 60 766-771
28 Scott-Coombs D M. Peritoneal cytokine response in surgery. Br J Surg. 1994; 81 756
29 Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 1992; 60 85-90
30 Chikaraishi A, Hirahashi J, Takase O et al.. Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells. Eur J Pharmacol. 2001; 427 151-158
31 Yanagi T, Watanabe M, Fukuda S, Tsuji Y. Suppressive effects of tranilast (TN) on human mononuclear cells. Jpn J Inflammation. 1987; 7 169-176
32 Mori H, Tanaka H, Kawada K, Nagai H, Koda A. Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis. Jpn J Pharmacol. 1995; 67 279-289
33 Ward M R, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-b system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002; 22 940-948
34 Raftery A T. Effect of peritoneal trauma on peritoneal fibrinolytic activity and intraperitoneal adhesion formation. An experimental study in the rat. Eur Surg Res. 1981; 13 397-401
35 DiZerega G S, Campeau J D. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update. 2001; 7 547-555
36 Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signaling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol. 1999; 127 537-545
37 Isaji M, Miyata H, Ajisawa Y, Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol. 1997; 122 1061-1066
38 Squires C E, Escobar G P, Payne J F et al.. Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol. 2005; 39 699-707
39 Yasukawa T, Kimura H, Dong J et al.. Effect of Tranilast on proliferation, collagen gel contraction, and transforming growth factor beta secretion of retinal pigment epithelial cells and fibroblasts. Ophthalmic Res. 2002; 34 206-212
40 Li Y, Foster W, Deasy B M et al.. Transforming growth factor-β1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol. 2004; 164 1007-1019
41 Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol. 2002; 161 895-907
42 Huard J, Yong L, Ferddie H. Muscle injuries and repair: current trends in research. J Bone Joint Surg Am. 2002; 84 822-832
43 Border W A, Noble N A. Transforming growth factor-β in tissue fibrosis. N Engl J Med. 1994; 10 1286-1292
44 Branton M H, Kopp J B. TGF-beta and fibrosis. Microbes Infect. 1999; 1 1349-1365
45 Bernasconi P, Torchiana E, Confalonieri P et al.. Expression of transforming growth factor-β1 in dystrophic patient muscles correlates with fibrosis. Pathogenic role of a fibrogenic cytokine. J Clin Invest. 1995; 96 1137-1144
46 Lundberg I, Ulfgren A, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997; 40 865-874
47 Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell S R. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo). 1994; 116 892-897
48 Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol. 1992; 60 91-96
49 Suzawa H, Kikuchi S, Ichikawa K et al.. Effect of tranilast, an antiallergic drug, on human keloid tissues. Nippon Yakurigaku Zasshi. 1992; 99 231-239
50 Ichikawa K, Suzawa H, Tsuchiya O et al.. Comparison of the effects of tranilast, triamcinolone, and a heparin-like substance on keloid and hypertrophic scar. Oyo Yakur. 1992; 43 401
51 Cohen I K, Keiser H R, Sjoerdsma A. Collagen synthesis in human keloid and hypertrophic scar. Surg Forum. 1971; 22 488-489
52 Shigeki S, Murakami T, Yata N, Ikuta Y. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg. 1997; 31 151-158
53 Taniguchi S, Yorifuji T, Hamada T. Treatment of linear localized scleroderma with the anti-allergic drug, Tranilast. Clin Exp Dermatol. 1994; 19 391-393
54 Pinto Y M, Pinto-Sietsma S J, Philipp T et al.. Reduction in left ventricular messenger RNA from transforming growth factor beta (1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension. 2000; 36 747-754
55 Mifsud S, Kelly D J, Qi W et al.. Intervention with tranilast attenuates renal pathology and alburminuria in advanced experimental diabetic neuropathy. Nephron Physiol. 2003; 95 83-91
56 Martin J, Kelly D J, Mifsud S A et al.. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res. 2005; 65 691-694
57 Guidry C. The role of Muller cells in fibrocontractive retinal disorders. Prog Retin Eye Res. 2005; 24 75-86
58 Hocher B, Godes M, Olivier J et al.. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens. 2002; 20 745-751
59 Ward M R, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor β system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol. 2002; 22 940-948
60 Tamai H, Katoh O, Suzuki S et al.. Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J. 1999; 138 968-975
61 Holmes Jr D R, Savage M, LaBlanche J M et al.. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002; 106 1243-1250
62 Kosuga K, Tamai H, Ueda K et al.. Effectiveness of tranilast on restenosis after directional coronary atherectomy. Am Heart J. 1997; 134 712-718
63 Okada H, Kalluri R. Cellular and molecular pathyways that lead to progression and regression of renal fibrogenesis. Curr Mol Med. 2005; 5 467-474
64 Kelly D J, Zhang Y, Gow R, Gilbert R E. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol. 2004; 15 2619-2629
65 Soma J, Sugawara T, Huang Y D, Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron. 2002; 92 693-698
66 Cooper K, Young J, Wadsworth S, Cui H, diZerega G S, Rodger K E. Reduction of post-surgical adhesion formation with Tranilast. J Surg Res. 2007; 141(2) 153-161
67 Young J, Wadsworth S, Cooper K, Rosenblatt J, Cui H. Drug-enhanced adhesion prevention. United States Patent Application Publication. US 2005/0106229 A1 2005
68 Dullerud R, Graver V, Haakonsen M, Haaland A K, Loeb M, Magnaes B. Influence of fibrinolytic factors on scar formation after lumbar discectomy. A magnetic resonance imaging follow-up study with clinical correlation performed 7 years after surgery. Spine. 1998; 23 1464-1469
69 Rodgers K E, Robertson J T, Espinoza T et al.. Reduction of epidural fibrosis in lumbar surgery with Oxiplex adhesion barriers of carboxymethylcellulose and polyethylene oxide. Spine J. 2003; 3 277-283
70 Jaibaji M, Brody G S, Rodgers K et al.. A new model for experimental tendon adhesions in the chicken. Ann Plast Surg. 2000; 44 205-210

Gere S diZeregaM.D.

University of Southern California, Keck School of Medicine, Department of Obstetrics and Gynecology, Livingston Reproductive Biology Laboratories

1321 N. Mission Road, Los Angeles, CA 90033

Email: GSD1270@aol.com